ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes.
Kenji MikiKohei DeguchiMisato Nakanishi-KoakutsuAntonio Lucena-CacaceShigeru KondoYuya FujiwaraTakeshi HataniMasako SasakiYuki NakaChikako OkuboMegumi NaritaIkue TakeiStephanie C NapierTsukasa SugoSachiko ImaichiTaku MonjoTatsuya AndoNorihisa TamuraKenichi ImahashiTomoyuki NishimotoYoshinori YoshidaPublished in: Nature communications (2021)
One of the earliest maturation steps in cardiomyocytes (CMs) is the sarcomere protein isoform switch between TNNI1 and TNNI3 (fetal and neonatal/adult troponin I). Here, we generate human induced pluripotent stem cells (hiPSCs) carrying a TNNI1EmGFP and TNNI3mCherry double reporter to monitor and isolate mature sub-populations during cardiac differentiation. Extensive drug screening identifies two compounds, an estrogen-related receptor gamma (ERRγ) agonist and an S-phase kinase-associated protein 2 inhibitor, that enhances cardiac maturation and a significant change to TNNI3 expression. Expression, morphological, functional, and molecular analyses indicate that hiPSC-CMs treated with the ERRγ agonist show a larger cell size, longer sarcomere length, the presence of transverse tubules, and enhanced metabolic function and contractile and electrical properties. Here, we show that ERRγ-treated hiPSC-CMs have a mature cellular property consistent with neonatal CMs and are useful for disease modeling and regenerative medicine.
Keyphrases
- induced pluripotent stem cells
- poor prognosis
- left ventricular
- endothelial cells
- binding protein
- skeletal muscle
- single cell
- heart failure
- cell therapy
- high glucose
- stem cells
- pluripotent stem cells
- crispr cas
- mesenchymal stem cells
- dna methylation
- gene expression
- protein kinase
- tyrosine kinase
- bone marrow
- protein protein